180
Participants
Start Date
June 16, 2025
Primary Completion Date
June 30, 2026
Study Completion Date
September 30, 2027
611
Double blind treatment period : 611 600 mg/450 mg at day 1，then 300 mg subcutaneous injection Q2W thereafter until week 16 Maintenance treatment period : 611 300 mg subcutaneous injection Q2W/Q3W until week 52.（The subjects in the placebo group during the double-blind treatment period need to be given a loading dose at week 16.）
Matching placebo
Double blind treatment period : placebo subcutaneous injection Q2W until week 16.
Peking University People's Hospital, Beijing
Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Nanchang
The Fourth Affiliated Hospital Zhejiang University School of Medicine, Jinhua
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
INDUSTRY